Novel safe and efficacious drugs with AI and cell biology.

InterAx Biotech AG

Incorporated

29.04.2016

Headquarters

Villigen

Support

InterAx developed a drug discovery and optimisation technology platform to go beyond target identification and ligand discovery. It is connecting AI and cell signalling to design drugs triggering a precisely defined cell pathway modulation. This unique combination enables to identify and optimise safer and more efficacious drug candidates rather than just generating them faster and cheaper, thus significantly de-risk their development process.

InterAx focuses on the design of drugs targeting G-Protein-Coupled Receptors, the largest class of human cellular receptors and targets of 40% of all marketed.

InterAx offers biopharma partners in need to gain in-depth insight for the design of high-quality drug candidates access to its technology platform.